The last drilling at Golconda took place in 2023, which unlocked some high grade silver zones with hits including 25.9m at ...

Stockhead’s ‘Garimpeiro’ columnist Barry FitzGerald is back in the studio for another instalment of The Explorers Podcast.

Investors were clearly feeling jittery on Wednesday, with many trimming positions in riskier assets amid a more uncertain ...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Fraser Palamara ...

Bank stocks, including CBA, see losses this morning Gold falls below US$2,600, hurting gold stocks; lithium drops on weak ...

Koba Resources’ step-out drilling has intersected significant uranium at the Chivas and Berber prospects at its Yarramba ...

Category four exploration works have been approved allowing C29 (ASX:C29) to carry out a range of tenement-wide activities at ...

The Trump administration is expected to liberalise research into psychedelic-assisted therapies – and Emyria investors have ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

The US election failed to deliver extra Chinese stimulus measures companies had been banking on, affecting copper and iron ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

The ASX 200 index slipped by 0.13% on Tuesday, extending Monday’s losses, as iron ore, gold, and energy stocks struggled.